vs
Side-by-side financial comparison of Via Transportation, Inc. (VIA) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Via Transportation, Inc. is the larger business by last-quarter revenue ($109.7M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). Via Transportation, Inc. runs the higher net margin — -33.6% vs -49.0%, a 15.4% gap on every dollar of revenue. Via Transportation, Inc. produced more free cash flow last quarter ($-31.8M vs $-84.7M).
Via Transportation, Inc. is an American technology company that provides software as a service (SaaS) and operations to improve public transportation networks for cities, transit agencies, schools and universities, healthcare providers, and corporations around the world. Via offers fully managed transit services as well as transportation planning tools, consulting services, operational support, and navigation.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
VIA vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $109.7M | $70.6M |
| Net Profit | $-36.9M | $-34.6M |
| Gross Margin | 39.3% | — |
| Operating Margin | -17.2% | -56.7% |
| Net Margin | -33.6% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-1.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $574.6M | $503.0M |
| Total Assets | $702.1M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $378.2M | $490.9M |
| Q3 25 | $574.6M | $503.0M |
| Q3 25 | $702.1M | $577.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-30.4M | $-84.6M |
| Free Cash FlowOCF − Capex | $-31.8M | $-84.7M |
| FCF MarginFCF / Revenue | -29.0% | -120.1% |
| Capex IntensityCapex / Revenue | 1.2% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-30.4M | $-84.6M |
| Q3 25 | $-31.8M | $-84.7M |
| Q3 25 | -29.0% | -120.1% |
| Q3 25 | 1.2% | 0.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VIA
| Government Customer | $103.7M | 95% |
| Commercial Customer | $5.9M | 5% |
VRDN
Segment breakdown not available.
